Zacks: Brokerages Anticipate American Renal Associates Holdings Inc (ARA) Will Post Quarterly Sales of $188.43 Million

Wall Street analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to post sales of $188.43 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for American Renal Associates Holdings’ earnings, with the highest sales estimate coming in at $189 million and the lowest estimate coming in at $188 million. American Renal Associates Holdings posted sales of $186.94 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 0.8%. The company is scheduled to announce its next earnings report on Tuesday, August 8th.

According to Zacks, analysts expect that American Renal Associates Holdings will report full-year sales of $188.43 million for the current financial year, with estimates ranging from $760.2 million to $767.4 million. For the next financial year, analysts anticipate that the company will report sales of $843.3 million per share, with estimates ranging from $837.9 million to $847 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for American Renal Associates Holdings.

American Renal Associates Holdings (NYSE:ARA) last released its quarterly earnings results on Tuesday, May 9th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by $0.04. American Renal Associates Holdings had a return on equity of 55.06% and a net margin of 1.92%. The company had revenue of $177 million for the quarter, compared to the consensus estimate of $184.67 million. During the same quarter last year, the firm posted $0.16 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year.

ARA has been the topic of a number of research reports. Wells Fargo & Co lowered shares of American Renal Associates Holdings from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 9th. Zacks Investment Research downgraded shares of American Renal Associates Holdings from a “hold” rating to a “strong sell” rating in a report on Thursday, March 9th. Finally, Barclays PLC lowered their target price on shares of American Renal Associates Holdings from $25.00 to $23.00 and set an “overweight” rating on the stock in a report on Thursday, March 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. American Renal Associates Holdings presently has a consensus rating of “Buy” and a consensus price target of $27.00.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/06/16/zacks-brokerages-anticipate-american-renal-associates-holdings-inc-ara-will-post-quarterly-sales-of-188-43-million-updated-updated-updated.html.

American Renal Associates Holdings (NYSE:ARA) traded up 2.20% during mid-day trading on Friday, hitting $17.21. 24,850 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $17.20 and a 200 day moving average of $19.89. American Renal Associates Holdings has a 52 week low of $15.47 and a 52 week high of $29.65. The stock’s market capitalization is $535.97 million.

A number of institutional investors have recently modified their holdings of ARA. FMR LLC increased its position in shares of American Renal Associates Holdings by 57.1% in the fourth quarter. FMR LLC now owns 3,488,954 shares of the company’s stock worth $74,245,000 after buying an additional 1,267,561 shares during the last quarter. Tamarack Advisers LP purchased a new position in shares of American Renal Associates Holdings during the third quarter worth $1,770,000. Vanguard Group Inc. increased its position in shares of American Renal Associates Holdings by 11.6% in the first quarter. Vanguard Group Inc. now owns 928,768 shares of the company’s stock worth $15,678,000 after buying an additional 96,196 shares during the last quarter. Penn Capital Management Co. Inc. increased its position in shares of American Renal Associates Holdings by 104.4% in the third quarter. Penn Capital Management Co. Inc. now owns 165,505 shares of the company’s stock worth $3,024,000 after buying an additional 84,525 shares during the last quarter. Finally, AMI Asset Management Corp increased its position in shares of American Renal Associates Holdings by 17.8% in the first quarter. AMI Asset Management Corp now owns 447,331 shares of the company’s stock worth $7,551,000 after buying an additional 67,725 shares during the last quarter. Institutional investors and hedge funds own 87.52% of the company’s stock.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

5 Day Chart for NYSE:ARA

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply